BeOne Medicines (ONC) Liabilities and Shareholders Equity (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $8.6 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 46.43% year-over-year to $8.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.7 billion (up 31.61% YoY) and the FY2025 annual result came in at $8.2 billion, up 38.3% from the prior year.
• Liabilities and Shareholders Equity grew to $8.6 billion in Q1 2026 per ONC's latest filing, from $8.2 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $8.6 billion in Q1 2026 and bottomed at $5.5 billion in Q4 2022.
• The 5-year median for Liabilities and Shareholders Equity is $5.9 billion (2024), against an average of $6.5 billion.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity plunged 35.78%; it then surged 46.43% in 2026.
• Tracing ONC's Liabilities and Shareholders Equity over 5 years: stood at $5.5 billion in 2022, then advanced by 5.91% to $5.8 billion in 2023, then climbed by 1.99% to $5.9 billion in 2024, then soared by 38.3% to $8.2 billion in 2025, then climbed by 4.46% to $8.6 billion in 2026.
• Per Business Quant, the three latest ONC Liabilities and Shareholders Equity figures stand at $8.6 billion (Q1 2026), $8.2 billion (Q4 2025), and $7.6 billion (Q3 2025).

Peer Comparison